Efficacy Of Abiraterone In The Treatment Of 12 Patients With Bone Metastasis Castrate-resistant Prostate Cancer

Objective:In European and American countries,the incidence of prostate cancer has ranked to the first in male malignant tumors,and has become the third largest malignant tumor in men worldwide.Due to the westernization of life style,aging population,and the popularity of PSA screening,the incidence and mortality rate of prostate cancer patientsin China have gradually increased in the past 20 years.As an androgen-dependent malignant tumor,the progression of prostate cancer relies on the androgen in the patient’s body to continuously stimulate the growth and survival of normal prostate cells or tumor cells and inhibit apoptosis.Castration therapy is initially effective in most prostate cancer patients with or without bone metastases.After 18-24 months of castration treatment,a large number of patients will progress from castrate-sensitiveprostate cancer to bone metastasis-resistant castration-resistant prostate cancer.As a neoadjuvant systemic treatment for prostate cancer,Abiraterone acetate combination with prednisone,can eliminate the potential of androgen by completely suppress androgen production of patients with mCRPCby inhibiting key enzymes in the androgen synthesis pathway to inhibit androgen synthesis,eventually effectively control the progression of prostate cancer.There are several studies at home and abroad supporting the use of abiraterone acetate combined with prednisone in the progress of treatment.This study evaluate the efficacy and safety with the following-up evaluation of mCRPC patientsduring the course of medication by abiraterone acetate combined with prednisone,to providenew clinical evidence for mCRPC patients’medications.Methods:Twelve patients with mCRPC who were admitted to the Department of Urology of Shandong Provincial Hospital from January 2016 to December 2017 were selected for regular follow-up observation.The patients were observed for the change of ostealgia,strength,physical activity,sleep quality,diet,blood work,and radiological appearance during the regular medicationto evaluate objective efficacy,evaluatethe efficacy and safety of abiraterone acetate combined with prednisone in the treatment of mCRPC were evaluated by combining the follow-up evaluation of general conditions during the course of medication.Results:The clinical efficacy of 12 patients treated in this hospital was evaluated.In addition to one case of ineffective,one case of death and one case of discontinuation,the remaining nine patients were all susceptible to abiraterone in combination with prednisone drug therapy.The quality of life and radiological performance were significantly improved.Abiraterone acetate controlled the patient’s progress safely and effectively,improving the patient’s quality of life.Conclusions:As a new adjunctive treatment for prostate cancer.abiraterone acetate in the combination with prednisonecan inhibit male hormones by inhibiting key enzymes in the androgen synthesis pathway(17α hydroxylase and C17,20 side chain lyase)in the treatment of mCRPC patients,which safely and effectively controls the progression of prostate cancer in most of patients with mCRPC,and no significant side effects and adverse reactions to the patient’s blood work indicators,improved the quality of patients’ life,and controlled the progression of mCRPC.This study found that abiraterone acetate has certain short-term clinical efficacy for most patients with mCRPC,and it can guarantee more stable drug safety than other therapy.During the regular medication almost no toxic side effects,there is a good application prospects in the future.